NO995620L - Antiviral combinations containing carbocyclic nucleoside 1592U89 - Google Patents

Antiviral combinations containing carbocyclic nucleoside 1592U89

Info

Publication number
NO995620L
NO995620L NO995620A NO995620A NO995620L NO 995620 L NO995620 L NO 995620L NO 995620 A NO995620 A NO 995620A NO 995620 A NO995620 A NO 995620A NO 995620 L NO995620 L NO 995620L
Authority
NO
Norway
Prior art keywords
combinations containing
carbocyclic nucleoside
containing carbocyclic
antiviral combinations
antiviral
Prior art date
Application number
NO995620A
Other languages
Norwegian (no)
Other versions
NO995620D0 (en
Inventor
David Walter Barry
Clair Martha Heider St
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO995620D0 publication Critical patent/NO995620D0/en
Publication of NO995620L publication Critical patent/NO995620L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives terapeutiske kombinasjoner av (-)-(1S,4R)-4-[2-amino-6- (cyklopropylamino)-9H-purin-9-yl]-2-cyk!openten-1-metanol (1592U89) og ikke- nukleoside revers transkriptaseinhibitorer som har anti-HIV-virkning: Det beskrives også farmasøytiske blandinger som inneholder de nevnte kombinasjoner og deres anvendelse ved behandlingen av HIV-infeksjoner.Therapeutic combinations of (-) - (1S, 4R) -4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopenten-1-methanol (1592U89) are described. Non-nucleoside reverse transcriptase inhibitors that have anti-HIV activity: Also disclosed are pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections.

NO995620A 1997-05-17 1999-11-16 Antiviral combinations containing carbocyclic nucleoside 1592U89 NO995620L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations
PCT/EP1998/002836 WO1998052570A1 (en) 1997-05-17 1998-05-14 Antiviral combinations containing the carbocyclic nucleoside 1592u89

Publications (2)

Publication Number Publication Date
NO995620D0 NO995620D0 (en) 1999-11-16
NO995620L true NO995620L (en) 2000-01-14

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995620A NO995620L (en) 1997-05-17 1999-11-16 Antiviral combinations containing carbocyclic nucleoside 1592U89

Country Status (12)

Country Link
EP (1) EP0979082A1 (en)
JP (1) JP2001525839A (en)
AR (1) AR012702A1 (en)
AU (1) AU7912398A (en)
BR (1) BR9809127A (en)
CA (1) CA2289655A1 (en)
CO (1) CO4950569A1 (en)
HR (1) HRP980264A2 (en)
MA (1) MA26496A1 (en)
NO (1) NO995620L (en)
PE (1) PE74799A1 (en)
WO (1) WO1998052570A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
CO5070643A1 (en) * 1998-05-27 2001-08-28 Merck & Co Inc FORMULATION IN COMPRESSED TABLETS
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
WO2013111147A1 (en) * 2011-12-19 2013-08-01 Hetero Research Foundation Extended release compositions of nevirapine
WO2014133085A1 (en) * 2013-02-27 2014-09-04 国立大学法人京都大学 Pharmaceutical composition for prevention and/or treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
HRP980264A2 (en) 1999-02-28
WO1998052570A1 (en) 1998-11-26
AR012702A1 (en) 2000-11-08
JP2001525839A (en) 2001-12-11
CA2289655A1 (en) 1998-11-26
PE74799A1 (en) 1999-08-13
MA26496A1 (en) 2004-12-20
CO4950569A1 (en) 2000-09-01
BR9809127A (en) 2000-08-01
AU7912398A (en) 1998-12-11
EP0979082A1 (en) 2000-02-16
NO995620D0 (en) 1999-11-16

Similar Documents

Publication Publication Date Title
ATE185483T1 (en) ANTIVIRAL NUCLEOSIDE COMBINATION
TR200102313T2 (en) As antiviral agents (1R, SíS) -4- (6-amino-9H-purin-9-yl) -2-cyclopentene-1-methanol n mono-, di and tri-phosphate esters and phosphoramidates
HUP9801571A2 (en) Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc
FR16C0028I2 (en) VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
NO20053817L (en) Preparations and Methods for Antiviral Combination Therapy.
MX9204454A (en) THIOUREA DERIVATIVES TO INHIBIT THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS AND THE PHARMACEUTICAL FORMULATE CONTAINING THEM.
BRPI0313664B8 (en) nucleoside phosphorylase and nucleosidases inhibitor compounds, their compositions and their uses
DK1469843T3 (en) Composition for pharmaceutical or dietetic use to combat hair loss
BR0307410A (en) Use of pde5 inhibitors in the treatment of healing and fibrosis
NO995620L (en) Antiviral combinations containing carbocyclic nucleoside 1592U89
NO942303L (en)
NO986034L (en) Combinations comprising VX 478, ZidovudÞn, FTC and / or 3TC for use in the treatment of HIV
BG103959A (en) Carbocyclic nucleoside hemisulphate and its application in the treatment of viral infections
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
DK0479093T3 (en) Oligosaccharide derivatives and their use as drugs
DK0777669T3 (en) 4- [2-Amino-6- (cyclopropylamino) -9H-purin-yl] -2-cyclopenten-1-methanol succinate as an antiviral agent
NO983090L (en) Therapeutic compounds
MY105855A (en) Therapeutic nucleotides.
NO995621L (en) Antiviral combinations containing carbocyclic nucleoid 1592U89
EA199700150A1 (en) COMBINED TREATMENT WITH RESPECT OF HIV INFECTION USING HIV PROTASE INHIBITOR INDINAVIAR AND REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, ddI OR ddC
WO2002069943A3 (en) Use of pyrimidine nucleosides and/or the prodrugs thereof for combating the side-effects of haart (highly active anti-retroviral therapy) and other anti-viral therapies
TR199801439T2 (en) Nucleoside analogues in the combined therapy of herpes simplex infections.
MXPA04004061A (en) Antiretroviral pyridine and quinoline derivatives.
WO2002092062A3 (en) Combination of vitamin d analogue and pyrimidine nucleoside analogue
NO991589L (en) Novel 3-, 5- and / or 6-substituted analogues of swainsonine, methods for their preparation and their use as therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application